Call for Proposals: Supporting the Completion of High-Impact Randomized Controlled Trials

The Accelerating Clinical Trials/Accélérer les Essais Cliniques (ACT/AEC) Consortium is pleased to announce a call for proposals entitled “Supporting the Completion of High-Impact Randomized Controlled Trials”. The purpose of this call for proposals is to provide support for the completion of high-impact randomized controlled trials in order to advance clinical research and improve health outcomes. Eligible applicants must meet certain criteria and submit an application in accordance with the instructions provided. We encourage all interested parties to apply and look forward to reviewing your proposals.

The first ACT call for proposals is designed to support ongoing and active, Canadian-led, high-impact randomized controlled trials (RCTs) that need additional funding for successful completion and will publicly report their results by January 15, 2025.

Application instructions
  • Please combine the following application components into a single PDF:
    • Written proposal: Maximum of 3 pages if written in English or 4 pages if written in French (see formatting requirements in section titled, Proposal Sections and Adjudication Criteria in the RFA document); includes 1 page trial summary
    • References, figures, or tables (optional, up to 1 page)
    • Letter of support from an ACT Network (up to 1 page)
    • Most recent version of the protocol, and preferably also including the most recent version of the statistical analytic plan
  • Submit the full application to by noon EST on April 3rd, 2023 
    • Once submitted, written confirmation of receipt will be provided within 24 hours of submission. If you do not hear back within 24 hours, please follow up to ensure successful delivery.
Eligibility criteria

For a trial to be eligible for this opportunity, it must fulfill each of the following points:

  • Be registered with an organization such as;
  • Be led by a Canadian researcher who is a member(s) of an ACT Network; the principal investigator(s) of any trial can only submit 1 application to this competition;
  • Have a letter of support from an ACT Network (e.g. CDTRP); each Network can provide a maximum of 3 support letters to this competition, and;
  • Agree funds will be transferred to an organization eligible to hold CIHR funds; this organization will ensure and report that funds were used for CIHR eligible expenses, and the researchers will acknowledge ACT Consortium partnership and funding in all related presentations and publications.
About the Accelerating Clinical Trials/Accélérer les Essais Cliniques Consortium

On January 19th, the Canadian Institutes for Health Research (CIHR) formally announced that the Accelerating Clinical Trials/Accélérer les Essais Cliniques (ACT/AEC) Canada Consortium was the successful applicant for the federal grant for a 3-year term.

The ACT/AEC Canada Consortium consists of hundreds of investigators, patient-partners, healthcare professionals, government, and the biotechnology industry, as well as highly qualified personnel (e.g., study coordinators, biostatisticians) at 28 research networks and 11 clinical trial units located across the country, to address operational bottlenecks to conducting clinical trials in Canada. The ACT/AEC Consortium spans from Nova Scotia to British Columbia and Nunavut.